Beta-adrenoceptor agonists do not stimulate daytime melatonin secretion in healthy subjects. A double blind placebo controlled study.
Noradrenergic stimulation of pineal beta-adrenoceptors results in melatonin secretion. To investigate beta-adrenoceptor mediated plasma melatonin responses in humans, ritodrine, salbutamol (beta 2-adrenoceptor agonists) and dobutamine (beta 1-adrenoceptor agonist) were infused from 0900 to 1200 h to 8 healthy subjects (four men and four women) in a double blind, crossover, placebo controlled study. Ritodrine and salbutamol significantly increased plasma cyclic AMP and decreased serum potassium concentrations indicating the presence of beta 2-adrenoceptor stimulation. Dobutamine substantially increased systolic blood pressure corresponding to its beta 1-adrenoceptor agonist propriety. However, neither beta 2- nor beta 1-adrenoceptor stimulation modified plasma melatonin concentration. These results show that beta-adrenoceptor agonists do not increase daytime plasma melatonin concentration.
Berlin
I
I
Department of Clinical Pharmacology, Hôpital Pitié-Salpêtrière, Paris, France.
Touitou
Y
Y
Guillemant
S
S
Danjou
P
P
Puech
A J
AJ
D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000328:Adult; D000420:Albuterol / Q000494:pharmacology; D018592:Cross-Over Studies; D004280:Dobutamine / Q000494:pharmacology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008550:Melatonin / Q000378:metabolism*; D012312:Ritodrine / Q000494:pharmacology
D000318:Adrenergic beta-Agonists; D004280:Dobutamine; D012312:Ritodrine; D008550:Melatonin; D000420:Albuterol